4D Molecular Therapeutics exchanges 6.6M shares for pre-funded warrants with RA Capital and BVF

4D Molecular Therapeutics, Inc.

RA Capital exchanged 4,850,000 shares for a warrant to acquire 4,850,000 shares.
BVF exchanged 1,750,000 shares for a warrant to acquire 1,750,000 shares.
Post-exchange shares outstanding as of Jan 23, 2026: 51,007,874; warrants exercisable for 16,935,665 total shares.
Warrants have $0.0001 exercise price, no expiration, and 4.99%/9.99% beneficial ownership blocker.
Issued in reliance on Section 3(a)(9) exemption from registration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.